The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

• Main Authors: Martin Vališ (Author), Anat Achiron (Author), Hans Peter Hartung (Author), Jan Mareš (Author), Veronika Tichá (Author), Pavel Štourač (Author), Simona Halusková (Author), Francesco Angelucci (Author), Zbyšek Pavelek (Author)
• Formato: Livro
• Publicado em: Adis, Springer Healthcare, 2023-08-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to several Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved medications that slow disease progression by immunomod...